Figure 10 Assessment of myocardial fibrosis

Slides:

Advertisements

Similar presentations

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Assessment of Nonischemic Myocardial Fibrosis J.

Advertisements

Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Therapeutic Targets in Heart Failure: Refocusing.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Myocardial Perfusion Reserve and Strain-Encoded.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Defining the Natural History of Uremic Cardiomyopathy.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Fibrosis With Mortality and Sudden.

Figure 1 Initial management of a patient with acute heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Velocity-encoded imaging (phase contrast mapping) to assess trans- and paravalvular regurgitation after transcatheter aortic valve replacement (TAVR).

Three cases illustrating the importance of the endocardial extent of infarction and its location for the QRS score. A. A small transmural, non–Q wave myocardial.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Reproduced with permission from Yancy, C. W. et al. 2017

Radiation-Induced Cardiac Valve Disease

Figure 5 BMI and cardiorespiratory fitness levels

Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 1 Cine cardiovascular magnetic resonance (CMR)

Figure 3 T1 mapping and late gadolinium enhancement (LGE)

Figure 4 BMI and mortality in patients with heart failure

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Risk stratification in hypertrophic cardiomyopathy (HCM)

Figure 2 Three-year survival rates on the basis of body composition

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 3D printing of aortic and mitral valves

Figure 8 4D magnetic resonance imaging patterns

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 6 Speckle tracking echocardiography to

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Imaging of atherosclerotic plaque burden

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Sudden cardiac death: The role of imaging

Figure 1 Decision tree integrating the assessment,

Figure 4 TAVI for bicuspid aortic valve disease

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Johannes Steiner et al. JACC 2017;70:

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Genotype-positive hypertrophic

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Apical hypertrophy missed by echocardiography

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The neurogenic components of angina

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Matrix signals regulate valve cell phenotypes

Nat. Rev. Cardiol. doi: /nrcardio

Comparison of CMR and echocardiography in aortic regurgitation.

Figure 3 Imaging of adverse plaque characteristics

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Multimodality imaging of aortic stenosis.

Ingrid Kindermann et al. JACC 2012;59:

Cardiac magnetic resonance imaging of the heart in a patient with pulmonary arterial hypertension. a) Short axis image. #: dilated right ventricle; ¶:

Nat. Rev. Cardiol. doi: /nrcardio

Presentation transcript:

Figure 10 Assessment of myocardial fibrosis with late gadolinium-enhanced (LGE) cardiac magnetic resonance (CMR) Figure 10 | Assessment of myocardial fibrosis with late gadolinium-enhanced (LGE) cardiac magnetic resonance (CMR). a,b | LGE CMR imaging and histopathology, respectively, of a patient with severe aortic regurgitation. A small amount of myocardial fibrosis on LGE CMR (0.8%) corresponded with interstitial fibrosis (12.6%) on histology using picrosirius red staining. c,d | Conversely, in a patient with severe aortic regurgitation, LGE CMR reveals substantial myocardial replacement fibrosis (9.44%) corresponding with 42.7% on histopathology. Reproduced from Azevedo, C. F. et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J. Am. Coll. Cardiol. 56, 278–287 (2010), with permission from Elsevier. Reproduced from Azevedo, C. F. et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J. Am. Coll. Cardiol. 56, 278–287 (2010), with permission from Elsevier Bax, J. J. & Delgado, V. (2017) Advanced imaging in valvular heart disease Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.1